Beckley Psytechs Phase 2 Ergebnis zu Depression loest geplante Atai Life Sciences Fusion aus

Beckley Psytechs intranasal BPL-003 reduced depression symptoms in a Phase 2b trial in treatment-resistant depression, moving the program forward and triggering a planned merger. The trial included 193 patients and tested 8 mg and 12 mg doses versus a 0.3 mg comparator arm over eight weeks. A single 12 mg dose produced a statistically significant 11.1 point decrease in MADRS symptoms at Day 29 versus a 5.8 point decrease in the comparator arm, meeting the primary endpoint. The 8 mg dose also showed a similar 12.1 point MADRS reduction and met a key secondary endpoint. BPL-003 is a formulation of mebufotenin, also referred to as 5-MeO-DMT. Safety signals were reported as generally mild to moderate for adverse events, with no drug-related serious adverse events and no suicide-related safety signals. The results met criteria for Atai to proceed with the merger plan, with a proposed combined entity focused on short time in-clinic psychedelic-based mental health therapies.